MALVERN, Pa. (AP) _ Aclaris Therapeutics Inc. (ACRS) on Tuesday reported a loss of $18.2 million in its third quarter.
The Malvern, Pennsylvania-based company said it had a loss of 63 cents per share.
The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 86 cents per share.
The specialty pharmaceutical company posted revenue of $684,000 in the period.
Aclaris shares have fallen 12 percent since the beginning of the year. The stock has climbed 15 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ACRS at https://www.zacks.com/ap/ACRS